Abstract: The present invention relates to edible products and compositions for preparing edible products, particularly edible products suitable for use as confectionery and having therapeutic uses. In particular, it relates to products of the type referred to as gummies and jellies and to compositions and methods for the preparation thereof; and to their use as confectionery and in therapy, in particular in hydration therapies. We describe a gelling composition for preparing a gelled product. The gelling composition comprises or consists of Component A and Component B in a weight ratio of from 1:4 to 1.4:1. Component A comprises at least one rigid gel-forming agent and Component B comprises at least one flexibility modifier. In some examples, Component A and Component B are present in a weight ratio of from 1:4 to 1.5:1, or 1:3 to 1.5:1, or 3:4 to 4:3, or 4:5 to 5:4 or about 1:1.

Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of mlDH 1, and component B being a DNA hypomethylating agent. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease.

Abstract: A system for communicating within a vehicle includes a cabin manager unit (CMU) configured to perform operations. The operations include electronically removing a first panel from a network. The operations also include receiving an addition command signal to electronically add a second panel to the network to replace the first panel. The addition command signal is wireless. The operations also include ranking a plurality of frequency ranges used by the second panel based at least partially upon one or more metrics of the frequency ranges.

Abstract: A system for communicating within a vehicle includes a cabin manager unit (CMU) in the vehicle. The CMU is configured to perform operations including ranking a plurality of frequency ranges used by a panel in the vehicle based at least partially upon one or more metrics of the frequency ranges. The operations also include receiving a first command signal from the panel in a first of the frequency ranges. The first frequency range is selected based at least partially upon the ranking.

Abstract: A system for communicating within a vehicle includes a cabin manager unit (CMU) in the vehicle that is configured to communicate with a device in the vehicle through a wire and configured to communicate wirelessly with a panel in the vehicle. The CMU is configured to perform operations. The operations include transmitting a default state signal to the device. The operations also include transmitting an advertising signal to the panel. The operations also include ranking a plurality of frequency ranges used by the panel based at least partially upon one or more metrics of the frequency ranges. The operations also include assigning a first command signal to one of the frequency ranges based at least partially upon the ranking. The first command signal includes a command from a user received at the panel. The operations also include receiving the first command signal from the panel in the assigned frequency range.

Abstract: A system for communicating within a vehicle includes a cabin manager unit (CMU) in the vehicle. The CMU is configured to communicate with a device in the vehicle and configured to communicate wirelessly with a first panel in the vehicle. The CMU is configured to perform operations. The operations include electronically removing the first panel from the network in response to the first panel malfunctioning. The operations also include electronically adding a second panel to the network to replace the first panel. The CMU is configured to communicate wirelessly with the second panel. The operations also include ranking a plurality of frequency ranges used by the second panel based at least partially upon one or more metrics of the frequency ranges. The operations also include assigning a first command signal to one of the frequency ranges based at least partially upon the ranking.

Abstract: Save and synchronization status information is provided. The save and synchronization status information may be concise yet informative to a user and may provide an indication of the current save state of the document: “saved,” “dirty,” or “saving.” The indication of the current save state may be displayed in a consistent and reliable spot such that the user may reliably know where to look to find the document's save status. Other save states may be included, such as offline or error. The indication may be selectable, such that when selected, the user may see additional save and synchronization status detail, and may be enabled to rename the document.

Abstract: The present invention relates to * combinations of: ? component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2), or a physiologically acceptable salt, solvate, hydrate or ? stereoisomer thereof; ? component B: one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; ? in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially, ? dependently of one another by the oral, intravenous, topical, local installations, ? intraperitoneal or nasal route; * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; * a kit comprising such a combination; * use of biomarkers which is the loss of tumor suppressor PTEN or FBXW7, for predicting the sensitivi

Abstract: The present invention relates to combinations of: component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; component B: one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially, dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route; use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; a kit comprising such a combination; use of biomarkers which is the loss of tumor suppressor PTEN or FBXW7, for predicting the sensitivity and/or resistance

Abstract: The present invention relates to: use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of endometrial cancer (hereinafter abbreviated to “EC”), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis; combinations of a) said compound and b) one or more further active agents; a pharmaceutical composition comprising said compound as a sole active agent for the treatment of endometrial cancer (hereinafter abbreviated to “EC”), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis; a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; use of biomarkers which is the loss of tumor suppressor PTEN

Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract: Save and synchronization status information is provided. The save and synchronization status information may be concise yet informative to a user and may provide an indication of the current save state of the document: “saved,” “dirty,” or “saving.” The indication of the current save state may be displayed in a consistent and reliable spot such that the user may reliably know where to look to find the document's save status. Other save states may be included, such as offline or error. The indication may be selectable, such that when selected, the user may see additional save and synchronization status detail, and may be enabled to rename the document.

Abstract: This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administered to a Hepatocellular carcinoma (HCC) patient. Further the invention is directed to in-vitro methods for identifying mutated-type KRAS or NRAS gene in HCC patient and kits thereof.

Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

Abstract: The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein.

Abstract: Techniques to view and manage followed content are described. A technique may include receiving a selection to follow a content item. A reference to a content item selected for following may be stored for a user. The references for the user may be displayed in a centralized location in a user interface. The display may include contextual information about each followed content item with its reference. Additional information and functions for a followed content item may be displayed in response to a received selection for additional information. Other embodiments are described and claimed.

Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides methods of treating breast cancer using antibodies that bind to GPNMB, immunoconjugates and other derivatives thereof.

Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.